Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Change in Resistance Training Status Before Versus Since GLP-1 Receptor Agonist Initiation
研究概览
简要总结
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength) training before and after starting their medication.
GLP-1 medications are being prescribed more and more often to help people manage type 2 diabetes and lose weight. These medications work well, but a known side effect is that people can lose lean (muscle) tissue along with fat. Losing muscle can make it harder to move, do everyday tasks, and stay strong as we age. Resistance training, things like lifting weights, using resistance bands, or doing push-ups and squats, is the most effective way to keep and build muscle. Yet most adults in the United States do not meet the recommended amount of resistance training, and very little is known about the resistance training habits of people who take GLP-1 medications.
The purpose of this research is to systematically collect information from adults using GLP-1 medications so we can better understand: how often they do resistance training before and after starting the medication; what their sessions look like (frequency, duration, intensity, muscle groups); whether their resistance training is linked to how strong they feel and how well they can carry out daily activities; and what makes resistance training easier or harder while on a GLP-1 medication.
Findings will help doctors, dietitians, exercise professionals, and researchers design better guidance and interventions to protect muscle mass, physical function, and quality of life in people using GLP-1 medications.
Who can join: Adults 18 years or older who are currently taking a GLP-1 receptor agonist medication for type 2 diabetes, overweight or obesity, or weight management, and who have been on the medication for at least three months at a stable dose. Participants must be able to read and respond to the survey in English. People who are pregnant or planning bariatric surgery within the next three months are not eligible.
What participants will do: The study is a single, anonymous, online survey. Interested individuals click the survey link, review a short consent page, and indicate their willingness to participate. Eligible participants then answer questions about their background, current health, GLP-1 medication and dose, resistance training habits before and after starting the medication, self-reported strength and function, and things that make resistance training easier or harder. There are no in-person visits, no exercise tests, and no blood draws.
How long it takes: About 10 minutes total, in one online session. There is no follow-up after the survey and no compensation is offered.
Data privacy: The survey is anonymous. No names, email addresses, or IP addresses are collected or linked to responses. The survey runs on Qualtrics, a secure, institution-approved platform hosted on Ohio State University servers.
The research team hopes to enroll up to 200-300 adults across the United States.
详细描述
Background and Rationale Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone released from enteroendocrine cells after a meal. It slows gastric emptying, limits maximum nutrient absorption, and helps prevent weight gain. GLP-1's actions also include preventing beta-cell death, promoting beta-cell proliferation, and regulating glucose metabolism. Originally used to improve outcomes in people with type 2 diabetes, GLP-1 receptor agonists (GLP-1RAs) have increasingly been prescribed for chronic weight management in individuals with overweight or obesity, with agents such as liraglutide 3 mg and semaglutide 2.4 mg approved for people with a body mass index of at least 30 kg/m2, or 27 kg/m2 with weight-related comorbidities. From 2019 to 2023, use of GLP-1RAs for weight loss in the United States rose from approximately 21,000 to 174,000 users, an increase of more than 700%.
A recognized side effect of GLP-1RA therapy is a reduction in lean tissue mass. Losses in lean mass can impair quality of life and physical function by decreasing strength, slowing gait speed, and increasing fatigue. Reductions in muscle mass may also heighten fall risk, worsen metabolic health, and limit patients' ability to perform activities of daily living independently.
Resistance training (RT) is the most effective strategy for preserving and building muscle mass and strength. The American College of Sports Medicine (ACSM) recommends that adults engage in RT at least 2-3 times per week at moderate to vigorous intensity, focusing on all major muscle groups. However, national surveillance data indicate that only about 30% of U.S. adults meet the muscle-strengthening guidelines. Despite emerging evidence that combining GLP-1RAs with structured exercise - particularly RT - can mitigate lean mass loss and optimize long-term metabolic and functional outcomes, little is known about patients' RT behavior before and after initiating GLP-1RA therapy.
This study aims to systematically collect self-reported data from adults using GLP-1RAs on their RT participation and adherence to ACSM-aligned guidelines before and after starting the medication, in order to identify gaps in RT engagement and generate practical recommendations for researchers and practitioners seeking to prevent lean mass loss, preserve physical function, and improve quality of life in this growing patient population.
Specific Aims and Hypotheses Aim 1: Quantify the prevalence of resistance training participation among adults using GLP-1RAs, both before and after initiating GLP-1RA therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult aged 18 years or older
- •Currently taking a GLP-1 receptor agonist medication
- •On the GLP-1 receptor agonist for at least 3 months
- •Using the GLP-1 receptor agonist for type 2 diabetes, overweight or obesity, and/or weight management (self-reported)
- •Stable GLP-1 receptor agonist dose for the past 4 to 8 weeks
- •Able to read and respond to the survey in English
- •Willing and able to provide informed consent electronically
排除标准
- •Currently or planning to become pregnant
- •Planned bariatric surgery within the next 3 months
- •Recent bariatric surgery (within the past 3 months) or other conditions that substantially alter resistance training capacity (e.g., advanced cancer cachexia, severe mobility-limiting conditions)
- •Unable to read or respond to the survey in English
结局指标
主要结局
Change in Resistance Training Status Before Versus Since GLP-1 Receptor Agonist Initiation
时间窗: Single cross-sectional online assessment (~10 minutes). Retrospective self-report of resistance training habits during a usual week before starting the GLP-1 medication and during a usual week since starting (participants on GLP-1RA ≥ 3 months at a stabl
Resistance training (RT) status is assessed via the Muscle-Strengthening Exercise Questionnaire - Long Form (MSEQ-Long; Shakespear-Druery et al., 2022), which captures weekly frequency (days/week), session duration (minutes/session), intensity (OMNI-RES 0-10 scale), muscle groups targeted (7 major groups), and type of muscle-strengthening exercise across four modes (weight machines, bodyweight, resistance bands or free weights, holistic). Each participant reports RT during a usual week BEFORE starting their GLP-1 receptor agonist medication and during a usual week SINCE starting the medication. The primary outcome is the proportion of participants meeting ACSM muscle-strengthening guidelines (≥ 2 days per week engaging all major muscle groups) at each recall period, and the within-person change between the two recall periods.
Change in Resistance Training Status Before Versus Since GLP-1 Receptor Agonist Initiation
时间窗: Day 1
Resistance training (RT) status is assessed via the Muscle-Strengthening Exercise Questionnaire - Long Form (MSEQ-Long; Shakespear-Druery et al., 2022), which captures weekly frequency (days/week), session duration (minutes/session), intensity (OMNI-RES 0-10 scale), muscle groups targeted (7 major groups), and type of muscle-strengthening exercise across four modes (weight machines, bodyweight, resistance bands or free weights, holistic). Each participant reports RT during a usual week BEFORE starting their GLP-1 receptor agonist medication and during a usual week SINCE starting the medication. The primary outcome is the proportion of participants meeting ACSM muscle-strengthening guidelines (≥ 2 days per week engaging all major muscle groups) at each recall period, and the within-person change between the two recall periods.
次要结局
- Resistance Training Dosage Patterns Compared to ACSM Guidelines(Single cross-sectional online assessment (~10 minutes). Retrospective self-report of resistance training habits during a usual week before starting the GLP-1 medication and during a usual week since starting (participants on GLP-1RA ≥ 3 months at a stabl)
- Resistance Training Dosage Patterns Compared to ACSM Guidelines(Day 1)